/Eli%20Lilly%20and%20Co_%20by%20Sergio%20Photone%20via%20Shutterstock.jpg)
With a market cap of $1.1 trillion, Eli Lilly and Company (LLY) is one of the world's largest pharmaceutical companies, focused on discovering, developing, manufacturing, and marketing innovative medicines for chronic diseases. The Indianapolis, Indiana-based company has become a leader in diabetes care, obesity treatments, immunology, oncology, and neuroscience.
Eli Lilly has been a standout performer over the past year, comfortably beating the broader market. LLY stock has increased 52.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 22.6%. The stock has cooled in 2026, rising 8.9% year to date compared to the S&P 500's 12.8% advance.
Looking closer, shares of the company have outpaced the iShares U.S. Pharmaceuticals ETF (IHE), which has gained 51.3% over the past year.
Eli Lilly delivered blockbuster FY2026 Q2 earnings on Aug. 5, reinforcing its dominance in the booming obesity and diabetes markets. It comfortably exceeded Wall Street's expectations, sending the stock 4.9% higher after the announcement. Revenue soared 47.7% year over year to $22.97 billion, while adjusted EPS of $8.38 beat consensus estimates by an impressive 27.3%, fueled by runaway demand for its blockbuster GLP-1 therapies, Mounjaro and Zepbound.
Riding this strong momentum, management raised its full-year 2026 guidance, boosting its revenue guidance to $85 billion-$87 billion, reflecting confidence in sustained growth across its diabetes and obesity franchise.
For the fiscal year ending in December 2026, analysts expect LLY’s adjusted EPS to climb 43.4% year over year to $34.71. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters.
Among the 29 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 22 “Strong Buy” ratings, three “Moderate Buys,” and four “Holds.”
The configuration is bearish than two months ago when the stock had 23 “Strong Buy” suggestions.
On July 28, Barclays analyst Emily Field maintained her "Buy" rating on Eli Lilly and assigned a $1,400 price target, highlighting confidence in the company's leadership in the fast-growing obesity and diabetes markets. The firm expects Lilly's robust product portfolio and innovative pipeline to continue driving strong financial performance.
The mean price target of $1,292.46 represents a 10.5% premium to LLY’s current price levels. The Street-high price target of $1,600 suggests a 36.8% potential upside.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
